PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Okyo reaches clinical trial agreement with Tufts

Novel therapy, OK-101, offers a potential way of relieving neuropathic corneal pain.

Okyo Pharma Limited – a company focused on ophthalmology – has announced a new collaboration with Tufts Medical Center.

The partnership involves a 40-patient open-label clinical study evaluating the safety and efficacy of OK-101 among patients with neuropathic corneal pain (NCP).

A novel therapeutic developed by Okyo, OK-101 offers a potential way of relieving various symptoms associated with NCP. Meanwhile, the open-label trial will deliver an opportunity to evaluate the safety and efficacy of OK-101 in a real-world clinical setting, fostering a better understanding of its potential benefits for patients.

The collaborative project is focused on evaluating OK-101 as a potential non-opioid analgesic to reduce neuropathic corneal pain, and the trial is anticipated to unfold over six to nine months.

Dr Gary Jacob, chief executive officer at OKYO, was optimistic about the trial’s prospects: “We are excited about OK-101’s dual combination of anti-inflammatory ocular activity and NCP-reducing activity and are eagerly awaiting the top-line data from the DED trial.”

He added: “But we are also eager to move forward with our plan to evaluate this drug to treat NCP, which has gained considerable significance this past year as a major unmet medical need for patients specifically diagnosed with this debilitating ocular condition.”

Vice-chair of research at Tufts Medical Center, Dr Pedram Hamrah: “NCP, which can exhibit as a severe, chronic or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion.

“However, there are no approved commercial treatments currently available for this condition, and consequently we are looking forward to initiating the clinical trial to investigate the potential efficacy of OK-101 to treat symptoms of NCP.”

NCP is a serious condition characterised by chronic and severe eye discomfort, leading to decreased quality of life for impacted patients.

There is currently no FDA-approved drug to treat NCP and it remains as a major unmet medical need for the ocular community.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026